Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 1 | -$0.93 | -$0.82 | -$0.87 |
Q2 2024 | 1 | -$0.89 | -$0.79 | -$0.83 |
Q3 2024 | 3 | -$0.88 | -$0.78 | -$0.82 |
Q4 2024 | 5 | -$0.80 | -$0.63 | -$0.72 |
Q1 2025 | 4 | -$0.91 | -$0.69 | -$0.80 |
Q2 2025 | 2 | -$0.86 | -$0.76 | -$0.80 |
Q3 2025 | 2 | -$0.71 | -$0.63 | -$0.66 |
Q4 2025 | 2 | -$0.47 | -$0.42 | -$0.44 |
Q1 2026 | 1 | $0.47 | $0.53 | $0.50 |
Q2 2026 | 1 | $0.51 | $0.58 | $0.54 |
Q3 2026 | 1 | $0.48 | $0.55 | $0.51 |
Q4 2026 | 1 | $0.47 | $0.54 | $0.50 |
Q1 2027 | 1 | $0.94 | $1.06 | $0.99 |
Q2 2027 | 1 | $0.98 | $1.11 | $1.03 |
Q3 2027 | 1 | $0.96 | $1.08 | $1.01 |
Q4 2027 | 1 | $0.97 | $1.10 | $1.02 |
Q1 2028 | 2 | $0.89 | $1.01 | $0.94 |
Q2 2028 | 2 | $1.09 | $1.24 | $1.15 |
Q3 2028 | 2 | $1.07 | $1.21 | $1.13 |
Q4 2028 | 2 | $1.09 | $1.23 | $1.15 |
UroGen Pharma Ltd. last posted its earnings results on Wednesday, November 6th, 2024. The company reported $-0.55 earnings per share for the quarter, topping analysts' consensus estimates of $-0.84 by $0.29. The company had revenue of 25.20 M for the quarter and had revenue of 82.71 M for the year. UroGen Pharma Ltd. has generated $-4 earnings per share over the last year ($-3.55 diluted earnings per share) and currently has a price-to-earnings ratio of -4.04. UroGen Pharma Ltd. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 12th, 2025 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
11/06/2024 | Q3 2024 | -$0.84 | -$0.55 | 0.29 | $24.20 M | $25.20 M |
08/13/2024 | Q2 2024 | -$0.82 | -$0.91 | -0.09 | $23.97 M | $21.85 M |
05/13/2024 | Q1 2024 | -$0.93 | -$0.97 | -0.04 | $18.78 M | |
04/29/2024 | Q4 2023 | -$0.72 | $23.53 M | |||
09/29/2023 | Q3 2023 | -$0.68 | $20.03 M | $20.85 M | ||
08/10/2023 | Q2 2023 | -$1.13 | -$1.03 | 0.1 | $20.12 M | $21.14 M |
05/11/2023 | Q1 2023 | -$1.39 | -$1.30 | 0.09 | $17.19 M | |
05/01/2023 | Q4 2022 | -$1.22 | $18.09 M | |||
11/10/2022 | Q3 2022 | -$1.22 | -$1.13 | 0.09 | $20.15 M | $16.10 M |
08/11/2022 | Q2 2022 | -$1.33 | -$1.18 | 0.15 | $17.22 M | $16.60 M |
05/10/2022 | Q1 2022 | -$1.36 | -$1.25 | 0.11 | $13.56 M | |
03/21/2022 | Q4 2021 | -$1.18 | -$1.27 | -0.09 | $16.17 M | |
11/15/2021 | Q3 2021 | -$1.26 | -$1.35 | -0.09 | $15.37 M | $11.35 M |
08/04/2021 | Q2 2021 | -$1.10 | -$1.17 | -0.07 | $11.76 M | $13.03 M |
05/13/2021 | Q1 2021 | -$1.26 | -$1.17 | 0.09 | $7.49 M | |
03/18/2021 | Q4 2020 | -$1.31 | -$1.38 | -0.07 | $7.97 M | |
11/09/2020 | Q3 2020 | -$1.47 | -$1.31 | 0.16 | $3.33 M | $3.46 M |
08/10/2020 | Q2 2020 | -$1.55 | -$1.44 | 0.11 | $396,167 | $372,000 |
05/07/2020 | Q1 2020 | -$1.61 | -$1.79 | -0.18 | $0 | |
03/02/2020 | Q4 2019 | -$1.69 | -$1.86 | -0.17 | $0 |
UroGen Pharma Ltd. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 12th, 2025 based off last year's report dates.
In the previous quarter, UroGen Pharma Ltd. (:URGN) reported $-0.55 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.84 by $0.29.
The conference call for UroGen Pharma Ltd.'s latest earnings report can be listened to online.
The conference call transcript for UroGen Pharma Ltd.'s latest earnings report can be read online.
UroGen Pharma Ltd. (:URGN) has a recorded annual revenue of $82.71 M.
UroGen Pharma Ltd. (:URGN) has a recorded net income of $82.71 M. UroGen Pharma Ltd. has generated $-3.55 earnings per share over the last four quarters.
UroGen Pharma Ltd. (:URGN) has a price-to-earnings ratio of -4.04 and price/earnings-to-growth ratio is -1.02.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED